Late-stage functionalisation has emerged as a valuable enabling tool within the arsenal of a medicinal chemist. As newer synthetic methods become developed for the generation of small molecules, so too has the chemical space that medicinal chemists will have access to. Of course, these methods are valuable to the R&D team – but did you know that late-stage functionalisation will also likely have an impact on the IP profession?